National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Emerging Biomarkers for Primary Prevention of Cardiovascular Disease

Myers, Gary L.; Christenson, Robert H.; Cushman, Mary; Ballantyne, Christie M.; Cooper, Gerald R.; Pfeiffer, Christine M.; Grundy, Scott M.; Labarthe, Darwin R.; Levy, Daniel; Rifai, Nader; Wilson, Peter W.F.

doi:10.1373/clinchem.2008.115899

Cited by 153 publications

(110 citation statements)

References 3 publications

Supporting

Mentioning

104

Contrasting

Unclassified

Order By: Relevance

“…Elevated hsCRP level has been consistently associated with cardiovascular disease and thus is recommended for risk assessment in patients with intermediate risk according to guidelines. [19][20][21] However, previous researches on the association between hsCRP and first stroke yielded conflicting results. 12,22,23 A large meta-analysis with a hsCRP values were divided into 3 levels (low risk, <1.0 mg/L; average risk, 1-3 mg/L; and high risk, >3 mg/L) by recommendation from the Centers for Disease Control and American Heart Association for primary prevention of cardiac disease.…”

Section: Discussionmentioning

confidence: 99%

High-Sensitive C-Reactive Protein Predicts Recurrent Stroke and Poor Functional Outcome

Li¹,

Wang²,

Meng³

et al. 2016

Stroke

View full text Add to dashboard Cite

A cute minor ischemic stroke and transient ischemic attack (TIA) are common, and patients with recent stroke or TIA are at high risk for subsequent stroke. It is estimated that 10% to 20% of these patients have a stroke within 3 months after the index event, most of which even occur within the first 2 days. [1][2][3][4] Though several clinical risk factors have been reported to be associated with recurrent stroke, these characteristics do not fully explain the risk of recurrence of stroke. 5 Inflammation is increasingly recognized as playing a central role in atherosclerosis and cardiovascular disease. 6 High-sensitive C-reactive protein (hsCRP), one of the most investigated inflammatory makers in cardiovascular research, has been independently associated with increased risk of recurrent cardiovascular events. 7 However, the association between hsCRP and recurrent stroke is less established. [8][9][10] On the contrary, disability from stroke has brought huge personal and societal burden. Though the predictive value of hsCRP in mortality has been proved, 11,12 its association with functional disability in the patients with stroke is still undefined. 13,14 The CHANCE (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events) trial showed that the combination of clopidogrel and aspirin was superior to aspirin alone in reducing recurrent stroke in patients with acute minor stroke or high-risk TIA during 90-day and 1-year Background and Purpose-Minor stroke and transient ischemic attack are common disorders with high rate of subsequent disabling stroke. We aim to investigate the role of high-sensitive C-reactive protein (hsCRP) in predicting recurrent stroke and poor functional outcome. Methods-In the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events (CHANCE) trial, 3044 (59%) consecutive patients from 73 (64%) prespecified centers had hsCRP levels measured. The primary outcome was any stroke within 90 days. The secondary outcome included combined vascular events and dependence or death defined as modified Rankin Scale score of 2 to 6 at 90 days and a new vascular event during 1-year follow-up. The associations of hsCRP with recurrent stroke and functional outcome were analyzed by using Cox proportional hazards and logistic regression models. Results-Elevated hsCRP (>3.0 mg/L) was observed in 32% of the study population. Patients with hsCRP >3 mg/L had an increased risk of recurrent stroke (adjusted hazard ratio, 1.46; 95% confidence interval, 1.08-1.98; P=0.039), ischemic stroke and combined vascular events, and poor functional outcome (adjusted odds ratio, 1.68; 95% confidence interval, 1.22-2.32; P=0.002) compared with those with hsCRP <1 mg/L within 90-day follow-up period. High hsCRP levels also independently predicted recurrent stroke during 1-year follow-up. There was no interaction of hsCRP levels with randomized antiplatelet therapy. Conclusions-High

show abstract

Section: Discussionmentioning

confidence: 99%

High-Sensitive C-Reactive Protein Predicts Recurrent Stroke and Poor Functional Outcome

Li¹,

Wang²,

Meng³

et al. 2016

Stroke

View full text Add to dashboard Cite

show abstract

“…Although HDL-C has protective effects for atherosclerosis development, this may not break down the inflammatory period. Clinical studies have showed that the risk of cardiovascular disease, myocardial infarctus, stroke, angina pectoris increased with high serum cystatin C concentrations [15,16]. Serum cystatin C concentrations of CAD group was higher than control group but this association was not statistically significant.…”

Section: Discussionmentioning

confidence: 89%

Evaluation of Relationship Between Serum Neopterin, Cystatin C and Coronary Heart Disease

Abuşoğlu¹

2016

Ann Clin Anal Med

View full text Add to dashboard Cite

Anahtar KelimelerNeopterin; Sistatin C; Ateroskleroz; Koroner Arter Hastalığı; Gensini Skoru Abstract Aim: It has been reported that neopterin, a key molecule for immun response organization, is released from active macrophages of atheromatous plaque and useful for cardiovascular risk stratification. The aim of this study was to investigate serum cystatin C and neopterin levels in patients with coronary artery disease and examine the relationship between these markers and cardiovascular risk factors. Material and Method: Coronary artery disease group and control group consisted of 75 subjects (61 males, 14 females, mean age 60.5±10) and 50 subjects (25 males, 25 females, mean age 56.9±10), respectively. Results: Serum neopterin concentrations were higher in coronary artery disease group compared to control group. A negative correlation was established between neopterin and high density lipoprotein cholesterol. Also, there was a positive correlation between Gensini score and cystatin C and neopterin. Discussion: Serum cystatin C and neopterin concentrations might be useful markers for determining the coronary artery disease's severity. According to this study, neopterin seems to be a stronger indicator of cardiovascular diseases compared to cystatin C. The positive correlation between Gensini score and the biochemical markers offers us a potential use of these markers in evaluating the disease's severity.

show abstract

“…The increase in the concentrations of BNP or NT-pro-BNP is associated with higher mortality in the following 2-7 years in the studied populations. However, the benefits of therapy based on these assessments are uncertain (25) .…”

Section: Bnp In the Assessment Of Cardiac Functionmentioning

confidence: 99%

B-type natriuretic peptide in the evaluation of cardiac function

Valle¹,

Boas²,

Vidal³

et al. 2013

J. Bras. Patol. Med. Lab.

View full text Add to dashboard Cite

B type natriuretic peptide (BNP) and its precursor, the inactive form of NT-pro-BNP, are currently the most studied laboratory parameters in the heart disease spectrum. The assessment of their blood concentrations provides invaluable information on the likelihood, severity and prognosis of the disease. The present review aims to describe the biological determinants, the factors that influence these peptide concentrations, the suggested cutoff values for the diagnosis of heart failure and the use of this biomarker in the assessment of cardiac function.

show abstract

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Emerging Biomarkers for Primary Prevention of Cardiovascular Disease

Cited by 153 publications

References 3 publications

High-Sensitive C-Reactive Protein Predicts Recurrent Stroke and Poor Functional Outcome

High-Sensitive C-Reactive Protein Predicts Recurrent Stroke and Poor Functional Outcome

Evaluation of Relationship Between Serum Neopterin, Cystatin C and Coronary Heart Disease

B-type natriuretic peptide in the evaluation of cardiac function

Contact Info

Product

Resources

About